Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2015', provides an overview of the Hospital Acquired Pneumonia (HAP)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hospital Acquired Pneumonia (HAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hospital Acquired Pneumonia (HAP) Overview 8
Therapeutics Development 9
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview 9
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 10
Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies 11
Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes 13
Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Hospital Acquired Pneumonia (HAP) - Products under Development by Companies 18
Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes 20
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 21
Achaogen Inc. 21
Adenium Biotech ApS 22
AstraZeneca PLC 23
Cardeas Pharma Corp. 24
Cubist Pharmaceuticals, Inc. 25
Dong-A Socio Group 26
F. Hoffmann-La Roche Ltd. 27
KaloBios Pharmaceuticals, Inc. 28
MedImmune, LLC 29
Meiji Seika Pharma Co., Ltd. 30
Melinta Therapeutics, Inc 31
Nabriva Therapeutics AG 32
Savara Inc. 33
Serendex Pharmaceuticals A/S 34
Tetraphase Pharmaceuticals Inc. 35
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(amikacin + fosfomycin) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(ceftazidime + avibactam sodium) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AA-139 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
arbekacin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
delafloxacin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
eravacycline - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
fosfomycin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
KB-001A - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
lefamulin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MEDI-3902 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MEDI-4893 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
molgramostim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Nu-2 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
plazomicin sulfate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pseudomonas aeruginosa vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pseudomonas and VAP conjugate vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Qn-2251 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RG-7929 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
tedizolid phosphate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
vancomycin hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Hospital Acquired Pneumonia (HAP) - Recent Pipeline Updates 81
Hospital Acquired Pneumonia (HAP) - Dormant Projects 105
Hospital Acquired Pneumonia (HAP) - Discontinued Products 106
Hospital Acquired Pneumonia (HAP) - Product Development Milestones 107
Featured News & Press Releases 107
Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA 107
Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline's Potential Activity in Treating Serious Respiratory Infections 107
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 108
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 110
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 110
Jan 07, 2013: Trius Therapeutics's Tedizolid Receives Qualified Infectious Disease Product Designation From FDA 111
Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2015 9
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H1 2015 21
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2015 22
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca PLC, H1 2015 23
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H1 2015 24
Hospital Acquired Pneumonia (HAP) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 25
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Group, H1 2015 26
Hospital Acquired Pneumonia (HAP) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 27
Hospital Acquired Pneumonia (HAP) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 28
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H1 2015 29
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 30
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H1 2015 31
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2015 32
Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H1 2015 33
Hospital Acquired Pneumonia (HAP) - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 34
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Assessment by Combination Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Hospital Acquired Pneumonia (HAP) Therapeutics - Recent Pipeline Updates, H1 2015 81
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2015 105
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2015 106